The Intertwined Tapestry of Sex and Mental Health: A Dialogue with Dr. Anshu Kulkarni

This article delves into the complex relationship between sexual activity and mental health, exploring how stress relief, satisfaction, and dysfunction can impact overall well-being. Through a conversation with Dr. Anshu Kulkarni, a Mumbai-based senior consultant psychiatrist, we gain insights into how sexual health intertwines with mental health, addressing issues specific to LGBTQ+ individuals and highlighting the importance of open communication and awareness in psychiatric care.

Extreme Heat Warning: How to Stay Safe and Avoid Heat Exhaustion

As prolonged periods of extreme heat continue, emergency room doctors are seeing an influx of patients suffering from heat exhaustion. This article provides crucial tips on how to stay safe during scorching temperatures, emphasizing the dangers of dehydration and the importance of protecting vulnerable individuals like infants and those with chronic conditions.

New Tick-Borne Virus Found in China: Wetland Virus Can Cause Neurological Disease

Scientists have discovered a new tick-borne virus in China called Wetland Virus (WELV) that can spread to humans and cause neurological complications. The virus, belonging to the orthonairovirus family, was first detected in a hospital patient in 2019 and has since been found in ticks, various animals, and even a small percentage of healthy forest rangers. While most infected individuals recovered, some experienced severe symptoms, including coma, suggesting the potential for serious neurological damage. The discovery highlights the importance of surveillance and research into emerging orthonairoviruses to understand their impact on human health.

Axsome Therapeutics Receives FDA Acceptance for Migraine Treatment NDA Resubmission

Axsome Therapeutics has received a positive signal from the FDA for its migraine treatment, AXS-07, with the acceptance of its resubmitted New Drug Application (NDA). This news could potentially diversify Axsome’s product portfolio and fuel further growth, alongside its existing products for major depressive disorder and narcolepsy. The FDA’s decision on the approval is expected on January 31, 2025.

Scroll to Top